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mtDNA mutations have been implicated in a great va-
riety of diseases, ranging from rare neuromuscular syn-
dromes, with acronyms such as KSS, MELAS, MERRF,
and NARP, to such common conditions as diabetes, Par-
kinson disease, and Alzheimer disease (Wallace et al.
1995). While the study of the role of mitochondrial mu-
tations in each of these diseases has helped to describe
and catalogue the spectrum and frequency of oxidative
phosphorylation disorders, it has not led to an under-
standing of the factors contributing to the two major
clinical and biological issues: penetrance and tissue spec-
ificity. These two issues are frequently lumped together
under the genotype-phenotype correlation heading, but,
since different molecular pathways may account for each
of the two mechanisms in question, keeping them sep-
arate may be warranted. Hearing loss due to mitochon-
drial mutations has, somewhat surprisingly, emerged as
the mitochondrial disease that is providing some of the
answers.
Hearing Loss Due to Mitochondrial Mutations
Hearing loss can be due to inherited, acquired, het-
eroplasmic, and homoplasmic mitochondrial mutations.
The mostly acquired mitochondrial mutations associ-
ated with the systemic neuromuscular syndromes noted
above, which frequently have hearing loss as one of their
clinical signs, are both the easiest to understand and the
least instructive. In these cases, the heteroplasmic mu-
tation(s) can generally be found at highest levels in
nerves and in muscle. Because of the higher energy re-
quirements of muscle and nerve tissue, and because small
numbers of dysfunctional muscle and nerve cells can
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interrupt the function of many neighboring normal cells,
mitochondrial DNA mutations in those tissues are
thought to be particularly harmful. It is not unexpected
that generalized neuronal dysfunction is also expressed
in the auditory system.
The first surprise in this area of research came with
the description of several families with both diabetes
mellitus and sensorineural hearing loss. They were found
to have inherited the heteroplasmic A3243G mutation
in the gene for tRNAleu(UUR), the very same mutation as-
sociated with the systemic mitochondrial encephalom-
yopathy, lactic acidosis and stroke-like symptoms (ME-
LAS) syndrome (Reardon et al. 1992; van denOuweland
et al. 1992). In none of these cases were other neuro-
logical symptoms present. Instead of the 3243 mutation,
one family had a heteroplasmic large deletion/insertion
event (Ballinger et al. 1992). This association between
diabetes mellitus, hearing loss, and mitochondrial mu-
tations has been confirmed in population studies of di-
abetic patients (Oka et al. 1993; Alcolado et al. 1994;
Kadowaki et al. 1994; Katagiri et al. 1994). For ex-
ample, Kadowaki et al. found the 3243 mutation in
2%–6% of diabetic patients in Japan, and 61% of their
patients with diabetes and the 3243 mutation had hear-
ing loss (Kadowaki et al. 1994). The hearing loss is sen-
sorineural, and it usually develops only after the onset
of diabetes.While the 3243mutation raises the questions
of penetrance and tissue specificity, the confounding fea-
ture of heteroplasmy makes an experimental approach
to these questions difficult. Percentages of mutated mi-
tochondrial chromosomes, even when associated with
quantitative estimates of their absolute number, do not
take into consideration the distribution differences either
between cells in the same area or between mitochondrial
organelles within the same cell. Unfortunately, these var-
iables are impossible to control, and they are probably
impossible to measure accurately.
Another condition associated with acquired hetero-
plasmic mutations and hearing loss is presbycusis, the
hearing loss that occurs with age in a significant pro-
portion of individuals. Since mtDNA mutations and the
resulting loss of oxidative phosphorylation activity seem
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to play an important role in the aging process (for a
review, see Nagley et al. 1993), it is not unlikely that
mitochondrial mutations in the auditory system can also
lead to presbycusis. We examined recently the spiral gan-
glion and membranous labyrinth from archival temporal
bones of five patients with presbycusis for mutations
within the mitochondrially encoded cytochrome oxidase
II gene (Fischel-Ghodsian et al. 1997a). Results indicated
that, when compared with controls, at least a portion
of people with presbycusis have a significant load of
mtDNA mutations in auditory tissue. Results also in-
dicated great individual variability in both quantity and
cellular location of these mutations. The greatest ad-
vantage of studying acquired mutations in the ear relates
to the availability of temporal bone tissue banks; these
banks have functional audiological data available, and
thus they allow correlation of measurable functional
status, histology, immunohistochemistry of oxidative
phosphorylation complexes, and mtDNA analysis.
The first homoplasmic mutation associated with non-
syndromic deafness was identified in an Arab Israeli ped-
igree, when the striking pattern of transmission only
through mothers was noted (Jaber et al. 1992; Prezant
et al. 1993). Most of the deaf family members had onset
of severe to profound sensorineural hearing loss during
infancy, but a minority of family members had onset
during childhood or even adulthood. The homoplasmic
A1555G mutation in the mitochondrial 12S rRNA gene
was identified as the pathogenic mutation, and the same
mutation was also found to predispose individuals to
aminoglycoside-induced hearing loss (Prezant et al.
1993). The postulated mechanism of aminoglycoside
susceptibility was that the 1555 mutation makes the
rRNA more similar to the bacterial rRNA, which is in-
volved in aminoglycoside-induced bactericidal activity
(Prezant et al. 1993). Subsequent binding experiments
have proven that point (Hamasaki and Rando 1997).
More generally, this family demonstrated that, even in
a homoplasmic model, the two basic questions of mi-
tochondrial genetics, penetrance and tissue specificity,
remain unanswered. Why does the same mutation cause
severe hearing loss in some family members but not in
others, and why is the ear the only organ affected?
While many pedigrees and individual patients with the
same A1555G mutation have been described subse-
quently, hearing loss in all of these cases occurred only
after aminoglycoside exposure (Fischel-Ghodsian et al.
1993, 1997b; Hutchin et al. 1993; Pandya et al. 1997).
However, three pedigrees in Zaire and Spain were de-
scribed recently, with family members who went deaf
with and without aminoglycosides (Matthijs et al. 1996;
El-Schahawi et al. 1997). The study by Estivill et al.
(1998) in this issue of the Journal is remarkable for two
reasons, both of which indicate a higher-than-expected
frequency of this mutation. First, of 70 families with
sensorineural hearing loss, the study describes 19 fam-
ilies with the 1555 mutation. Even if the selection pro-
cess led to a bias toward families with multiple affected
individuals, and even when only the individuals without
aminoglycoside exposure are considered, this represents
an unexpectedly high frequency of familial sensorineural
hearing loss due to the 1555 mutation. Second, the fact
that the mutation arose on different haplotypes indicates
both that it is likely that this mutation exists in other
populations and that it may not be rare. It is also in-
teresting to note that the onset of hearing loss in the
Spanish families was rarely congenital, in contrast to the
age at onset in the Arab Israeli pedigree.
Another close-to-homoplasmic inherited mutation
leading to hearing loss is the 7445 mutation. It was first
described in a family from Scotland, and it was con-
firmed and established in two unrelated pedigrees from
NewZealand and Japan (Reid et al. 1994; Fischel-Ghod-
sian et al. 1995; Sevior et al., in press). In two of these
pedigrees, such skin conditions as palmoplantar kera-
toderma also segregate in the maternal line (Sevior et
al., in press). Interestingly, in the Scottish pedigree the
penetrance of this mutation for hearing loss is quite low,
while in the New Zealand and Japanese pedigrees the
penetrance is very high. Thus, as in the Arab Israeli
pedigree, the mitochondrial mutation does not appear
to be sufficient by itself to cause hearing loss in these
pedigrees. It requires additional genetic or environmen-
tal factors that seem to be rare in the Scottish pedigree
and common in the New Zealand and Japanese pedi-
grees. The 7445 mutation is a silent change of both the
last nucleotide of the cytochrome oxidase I gene on the
heavy strand and the nucleotide immediately adjacent
to the 3′ end of the tRNASer(UCN) gene on the light strand.
Mechanistically, the mutation appears to interfere with
normal processing of the light-strand polycistronic
mRNA, and significant decreases both in the amount of
tRNASer(UCN) and in rates of mitochondrial protein syn-
thesis have been observed (Guan et al. 1997). In this
situation, the difference in penetrance appears to be due
to a difference in mitochondrial haplotype. In the New
Zealand pedigree, complete sequencing of the mtDNA
revealed three additional sequence changes in complex
I protein genes, two of which have also been labeled as
secondary Leber hereditary optic neuroretinopathy mu-
tations (Fischel-Ghodsian et al. 1995). Since these or
similar sequence changes are not present in the Scottish
pedigree, mitochondrial haplotype appears to account
for the differences in penetrance in this case.
Clinical Relevance
The major clinical relevance of mitochondrial muta-
tions to hearing loss remains the prevention of amino-
glycoside-induced hearing loss. In countries where ami-
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noglycosides are used commonly, aminoglycoside-
induced ototoxicity is the major cause of hearing loss
(presbycusis excluded). For example, in a study that re-
viewed all deaf-mutes in a district of Shanghai, 21.9%
had aminoglycoside-induced hearing loss, representing
167 individuals from a population of nearly half a mil-
lion (Hu et al. 1991). The 1555 mutation accounted for
at least 30% of these. In the United States, the 1555
mutation accounts for ∼15% of all cases of aminogly-
coside-induced deafness (Hu et al. 1991; Fischel-Ghod-
sian et al. 1997b). The difference in frequency may re-
flect use of aminoglycosides in the United States only for
severe in-hospital infection. These patients receive sig-
nificantly higher levels for more prolonged periods, and
they are more likely to have other medical conditions
that exacerbate or cause the hearing loss. Physicians
should inquire about a family history of aminoglycoside-
induced hearing loss prior to the administration of sys-
temic aminoglycosides and prior to local administration
of aminoglycosides into the cochlea as treatment for
Meniere disease. In addition, every individual with ami-
noglycoside-induced hearing loss should be screened for
at least the presence of the mitochondrial 1555 muta-
tion, since presence of themutationwill allow counseling
of all maternally related relatives to avoid aminogly-
cosides. Similarly, the description by Estivill et al. (1998)
indicates that it might not be unreasonable to screen
every individual with nonsyndromic hearing loss for the
mutation, unless maternal inheritance can clearly be ex-
cluded. Since the test is easily done, and since prevention
of hearing loss in maternal relatives can easily be ac-
complished, this may be cost-effective medical practice.
The tragic and avoidable hearing loss of at least 40 pa-
tients in the report by Estivill et al. (1998) is a case in
point. With the exception of aminoglycosides and mi-
tochondrial mutations in the 12S rRNA gene, there are
no proven preventive or therapeutic interventions for
mitochondria-related hearing impairments. Diagnosis of
such defects is useful for genetic counseling, however,
and is indicated in all families with an inheritance pat-
tern of hearing loss consistent with maternal transmis-
sion. Diagnosis of such defects may also be indicated in
all patients who have both diabetes mellitus and adult-
onset hearing loss.
Penetrance and Tissue Specificity
Why are some individuals in families with homo-
plasmic or near-homoplasmic 1555 or 7445 mutations
affected with severe hearing loss, while others have com-
pletely normal hearing? Study of the mitochondrial mu-
tations has identified three factors that could modulate
phenotypic expression. These factors all affect the level
of oxidative-phosphorylation capacity in the cell. The
first such factor is environmental agents, of which ad-
ministration of aminoglycosides, as a triggering event in
the case of the 1555 mutation, is the prime example. It
is likely that other as-yet-unrecognized environmental
factors could play similar, but perhaps less dramatic,
roles. Both diet and drugs that affect oxygen-radical
formation and breakdown come to mind. The second
factor is the rest of the mitochondrial genome; as noted
above, the 7445 mutation provides a dramatic example
of that effect. The third factor is nuclear genes, of which
the Arab Israeli pedigree is a good example. The entire
family lives in the similar environmental surroundings
of a small Arab village in Israel, and all maternal rel-
atives share the same mitochondrial haplotype. The
difference between family members with normal hear-
ing and those with congenital profound hearing loss
has been postulated to be due to nuclear genes, and
biochemical differences between lymphoblastoid cell
lines of hearing and of deaf family members provide
support for this hypothesis (Guan et al. 1996). A ge-
nomewide search led to the conclusion that this effect
is due to several or many genetic loci and not to one
major nuclear locus (author’s unpublished data). Thus,
the model that emerges to explain penetrance is a thresh-
old model—that is, a combination of environmental, mi-
tochondrial, and nuclear factors can push a cell over a
threshold, with dramatic clinical differences on either
side of the threshold.
The second major biological question relates to tissue
specificity: If a homoplasmic mutation affects oxidative
phosphorylation (the only known function of the human
mitochondrial chromosome and an essential process in
every nucleated cell of the human body), it is unclear
how the clinical defect remains confined to the cochlea
rather than affecting every tissue in the body. We have
proposed two different mechanisms in which the tissue
specificity in these as well as in some heteroplasmic mi-
tochondrial disorders can be explained (Bernes et al.
1993; Fischel-Ghodsian 1996). First, it is possible that
tissue-specific subunits of mitochondrial ribosomes or
oxidative-phosphorylation complexes interact specifi-
cally with the mitochondrial defect only in tissues in
which they are expressed, leading to insufficient oxi-
dative phosphorylation. Tissue-specific subunits for gen-
eral cellular processes, including oxidative phosphory-
lation, have been described (Arnaudo et al. 1992).
Second, it cannot be excluded that humanmitochondrial
genes have functions in addition to their functions in
oxidative phosphorylation. In this model the mitochon-
drial mutation would interfere with a tissue-specific sec-
ondary function of the mitochondrial gene, which also
has to make the cell more sensitive to changes in oxi-
dative-phosphorylation capacity. Precedent for part of
this hypothesis can be found in studies of mice and of
Drosophila melanogaster (Wang et al. 1991; Kobayashi
et al. 1993). For example, in addition to being involved
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in mitochondrial translation, the mitochondrial large-
rRNA gene in Drosophila melanogaster has also been
identified in the cytoplasm, where it induces pole cell
formation in embryos, a key event in the determination
of the germ line (Kobayashi et al. 1993).
The experimental approach to the problem of tissue
specificity in Leber hereditary optic neuroretinopathy
and in the Arab Israeli pedigree has in the past been the
search for nuclear factors based on penetrance. The hope
was that a single nuclear factor that would explain both
the penetrance and tissue specificity would emerge.With
the conclusion that such a single factor for penetrance
does not exist, even in the simplified model of the Arab
Israeli pedigree, the limits of the experimental ap-
proaches in humans are close. Major efforts over the
next years should focus on the identification or the de-
velopment of animal models of mitochondrial disorders,
followed by the use of established genetic methods to
identify the multiple factors contributing to both pen-
etrance and tissue specificity.
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